What is Antabio?
Antabio is dedicated to developing novel treatments for drug-resistant infections, a critical global health challenge identified by the CDC and WHO. The company's primary focus is on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Its lead program, MEM-ANT3310, is specifically designed to combat hospital-acquired infections caused by highly resistant pathogens such as carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE). This strategic capital infusion positions Antabio to advance its clinical programs and address the urgent need for effective antibiotics against superbugs.
How much funding has Antabio raised?
Antabio has raised a total of $38.3M across 3 funding rounds:
Share Placement
$2.8M
Series A
$8.6M
Series B
$26.9M
Share Placement (2017): $2.8M with participation from Carb-X
Series A (2017): $8.6M led by iXO Private Equity, IRDI SORIDEC Gestion, and Galia Gestion
Series B (2023): $26.9M supported by The AMR Action Fund and BNP Paribas Développement
Key Investors in Antabio
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs. They invest in biotechnology companies that are creating treatments for patients with life-threatening antimicrobial-resistant infections.
BNP Paribas Développement
BNP Paribas Développement is a subsidiary of the international banking group BNP Paribas, dedicated to investing its own funds to support the long-term development of SMEs and mid-sized companies (ETIs) for over 38 years. They also assist high-potential startups since 2016.
Carb-X
CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat dangerous drug-resistant bacteria. The organization focuses on creating a diverse pipeline of early-stage antibiotics, preventatives, rapid diagnostics, and other products aimed at preventing, diagnosing, and treating life-threatening bacterial infections.
What's next for Antabio?
With the recent major strategic investment, Antabio is poised for significant advancement in its clinical development pipeline. The company's focus on critical priority pathogens and life-threatening infections aligns with global health initiatives to combat antimicrobial resistance. This backing is likely to fuel further research and development, potentially enabling Antabio to move its lead program, MEM-ANT3310, through later-stage clinical trials and towards regulatory approval. The company's trajectory suggests a strong emphasis on strategic partnerships and continued innovation in the antibiotic space, aiming to establish a robust portfolio of treatments against the most challenging bacterial threats.
See full Antabio company page
